We use cookies to understand how you use our site and to improve your experience.
This includes personalizing content and advertising.
By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties.
You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Reasons to Retain TransMedics Stock in Your Portfolio for Now
Read MoreHide Full Article
Key Takeaways
TMDX's OCS technology drives transplant adoption by improving organ viability and reducing complications.
TMDX's Gen 3.0 platform, clinical studies and international expansion support long-term growth opportunities.
TMDX's Q2 gross margin fell 180 basis points to 59.6%, prompting a cut in its 2026 operating-margin outlook.
TransMedics Group, Inc. (TMDX - Free Report) is well-poised for growth in the coming quarters, courtesy of its strength in Organ Care System (OCS) technology. The optimism, led by strength in OCS technology, is expected to contribute further. However, concerns due to gross margin pressure persist.
This Zacks Rank #3 (Hold) company has lost 16.6% in the last three months against 12% growth in the industry. The S&P 500 has witnessed 3.6% decline in the said time frame.
The renowned organ transplant therapy provider has a market capitalization of $2.3 billion. TransMedics’ earnings yield of 1.96% compares favorably with the industry’s negative 2.3%. The company’s earnings surpassed the Zacks Consensus Estimate in two of the trailing four quarters, missed twice, with the average surprise being 13.45%.
Image Source: Zacks Investment Research
Factors Favoring TMDX’s Growth
Strength in OCS Technology Driving Adoption: TransMedics’ OCS revolutionizes organ transplantation by replacing passive cold storage with a dynamic, physiologic approach that perfuses donor organs with warm, oxygenated, nutrient-rich blood. This innovation minimizes ischemic injury, allows real-time organ assessment and significantly increases the viability of organs, especially hearts and lungs, donated after circulatory death, that would otherwise go unused.
As the only FDA-approved, portable platform offering warm perfusion for heart, lung and liver transplants, the OCS standardizes care, reduces post-transplant complications and sets a new clinical benchmark in organ preservation. This positions TransMedics as a leader in the multi-billion-dollar transplant market with limited competition.
Robust Pipeline Supporting Growth: TransMedics continues to advance its next-generation Gen 3.0 OCS platform for heart, lung and liver, incorporating redesigned hardware, software and automation to improve usability, reliability and operating efficiency. The company is also pursuing ENHANCE Part B and DENOVO studies to expand its addressable heart and lung transplant populations, potentially unlocking 2,000-5,000 additional U.S. cases annually. Meanwhile, OCS Kidney development is progressing toward clinical testing in 2027, targeting a significant opportunity to improve utilization of recovered donor kidneys.
International expansion, supported by investments in European aviation infrastructure and plans to establish transplant logistics hubs, is another key growth driver. These initiatives could support TransMedics' longer-term goal of exceeding 10,000 annual transplants, although clinical timelines, regulatory approvals and execution remain key factors to watch.
Mixed Q2 Results: TransMedics delivered mixed second-quarter 2026 results, with revenues beating expectations but earnings missing the mark. Record revenues were driven by higher OCS utilization, strong liver and heart transplant volumes and accelerating logistics services. However, adjusted earnings declined sharply year over year as the company increased investments in clinical programs, product development and growth infrastructure.
Positively, growth remained balanced across product and service revenues, gross margin improved sequentially and logistics profitability strengthened. The company also covered 86% of NOP air transport missions using its owned fleet, up from 82% in the first quarter, reflecting improving operating efficiency.
A Factor That Can Offset TMDX’s Gains
Gross Margin Under Pressure: TransMedics is prioritizing revenue growth over near-term profitability, with the impact becoming more evident in second-quarter 2026. Gross margin declined 180 basis points year over year to 59.6%, pressured by a higher mix of lower-margin services and temporary product costs. Management expects margins to remain around 59% over the next two to three years as it continues investing internationally.
Adjusted R&D nearly doubled to $31.6 million, while adjusted operating margin contracted 960 basis points to 13.6%. Consequently, management lowered its 2026 adjusted operating-margin outlook to 12.5%-14% from approximately 16%, primarily reflecting higher OCS Kidney investments. The PAD Aviation acquisition is expected to add further near-term margin pressure, suggesting earnings growth could continue to trail revenue growth during the investment cycle.
Estimate Trend
TransMedics is witnessing a stable earnings estimate revision trend for 2026. In the past 30 days, the Zacks Consensus Estimate for its earnings has remained stable at $1.31 per share.
The Zacks Consensus Estimate for the company’s third-quarter 2026 revenues is pegged at $181.8 million, indicating a 26.4% improvement from the year-ago quarter’s reported number.
Key Picks
Some better-ranked stocks from the broader medical space are OPKO Health (OPK - Free Report) , Globus Medical (GMED - Free Report) and Merit Medical Systems (MMSI - Free Report) .
OPKO Health, currently flaunting a Zacks Rank #1 (Strong Buy), reported a second-quarter 2026 adjusted loss of 1 cent per share, which surpassed the Zacks Consensus Estimate by 87.5%. Revenues of $163.6 million beat the Zacks Consensus Estimate by 24.7%. You can see the complete list of today’s Zacks #1 Rank stocks here.
OPK has an estimated earnings growth rate of 23.3% for 2026. The company’s earnings beat estimates in each of the trailing four quarters, the average surprise being 95.1%.
Globus Medical, currently carrying a Zacks Rank #2 (Buy), reported a second-quarter 2026 adjusted earnings per share (EPS) of $1.34, which surpassed the Zacks Consensus Estimate by 19.6%. Revenues of $789.6 million beat the Zacks Consensus Estimate by 0.4%.
GMED has an estimated long-term earnings growth rate of 12.4%. The company’s earnings beat estimates in each of the trailing four quarters, the average surprise being 27.9%.
Merit Medical Systems, carrying a Zacks Rank #2 at present, reported second-quarter 2026 adjusted EPS of $1.19, which beat the Zacks Consensus Estimate by 23.9%. Revenues of $418.8 million surpassed the Zacks Consensus Estimate by 3.5%.
MMSI has an estimated long-term earnings growth rate of 10.4%. Merit Medical Systems’ earnings surpassed estimates in the trailing four quarters, with the average surprise being 14.1%.
View the Zacks #1 Rank List
Image: Bigstock
Reasons to Retain TransMedics Stock in Your Portfolio for Now
Key Takeaways
TransMedics Group, Inc. (TMDX - Free Report) is well-poised for growth in the coming quarters, courtesy of its strength in Organ Care System (OCS) technology. The optimism, led by strength in OCS technology, is expected to contribute further. However, concerns due to gross margin pressure persist.
This Zacks Rank #3 (Hold) company has lost 16.6% in the last three months against 12% growth in the industry. The S&P 500 has witnessed 3.6% decline in the said time frame.
The renowned organ transplant therapy provider has a market capitalization of $2.3 billion. TransMedics’ earnings yield of 1.96% compares favorably with the industry’s negative 2.3%. The company’s earnings surpassed the Zacks Consensus Estimate in two of the trailing four quarters, missed twice, with the average surprise being 13.45%.
Image Source: Zacks Investment Research
Factors Favoring TMDX’s Growth
Strength in OCS Technology Driving Adoption: TransMedics’ OCS revolutionizes organ transplantation by replacing passive cold storage with a dynamic, physiologic approach that perfuses donor organs with warm, oxygenated, nutrient-rich blood. This innovation minimizes ischemic injury, allows real-time organ assessment and significantly increases the viability of organs, especially hearts and lungs, donated after circulatory death, that would otherwise go unused.
As the only FDA-approved, portable platform offering warm perfusion for heart, lung and liver transplants, the OCS standardizes care, reduces post-transplant complications and sets a new clinical benchmark in organ preservation. This positions TransMedics as a leader in the multi-billion-dollar transplant market with limited competition.
Robust Pipeline Supporting Growth: TransMedics continues to advance its next-generation Gen 3.0 OCS platform for heart, lung and liver, incorporating redesigned hardware, software and automation to improve usability, reliability and operating efficiency. The company is also pursuing ENHANCE Part B and DENOVO studies to expand its addressable heart and lung transplant populations, potentially unlocking 2,000-5,000 additional U.S. cases annually. Meanwhile, OCS Kidney development is progressing toward clinical testing in 2027, targeting a significant opportunity to improve utilization of recovered donor kidneys.
International expansion, supported by investments in European aviation infrastructure and plans to establish transplant logistics hubs, is another key growth driver. These initiatives could support TransMedics' longer-term goal of exceeding 10,000 annual transplants, although clinical timelines, regulatory approvals and execution remain key factors to watch.
Mixed Q2 Results: TransMedics delivered mixed second-quarter 2026 results, with revenues beating expectations but earnings missing the mark. Record revenues were driven by higher OCS utilization, strong liver and heart transplant volumes and accelerating logistics services. However, adjusted earnings declined sharply year over year as the company increased investments in clinical programs, product development and growth infrastructure.
Positively, growth remained balanced across product and service revenues, gross margin improved sequentially and logistics profitability strengthened. The company also covered 86% of NOP air transport missions using its owned fleet, up from 82% in the first quarter, reflecting improving operating efficiency.
A Factor That Can Offset TMDX’s Gains
Gross Margin Under Pressure: TransMedics is prioritizing revenue growth over near-term profitability, with the impact becoming more evident in second-quarter 2026. Gross margin declined 180 basis points year over year to 59.6%, pressured by a higher mix of lower-margin services and temporary product costs. Management expects margins to remain around 59% over the next two to three years as it continues investing internationally.
Adjusted R&D nearly doubled to $31.6 million, while adjusted operating margin contracted 960 basis points to 13.6%. Consequently, management lowered its 2026 adjusted operating-margin outlook to 12.5%-14% from approximately 16%, primarily reflecting higher OCS Kidney investments. The PAD Aviation acquisition is expected to add further near-term margin pressure, suggesting earnings growth could continue to trail revenue growth during the investment cycle.
Estimate Trend
TransMedics is witnessing a stable earnings estimate revision trend for 2026. In the past 30 days, the Zacks Consensus Estimate for its earnings has remained stable at $1.31 per share.
The Zacks Consensus Estimate for the company’s third-quarter 2026 revenues is pegged at $181.8 million, indicating a 26.4% improvement from the year-ago quarter’s reported number.
Key Picks
Some better-ranked stocks from the broader medical space are OPKO Health (OPK - Free Report) , Globus Medical (GMED - Free Report) and Merit Medical Systems (MMSI - Free Report) .
OPKO Health, currently flaunting a Zacks Rank #1 (Strong Buy), reported a second-quarter 2026 adjusted loss of 1 cent per share, which surpassed the Zacks Consensus Estimate by 87.5%. Revenues of $163.6 million beat the Zacks Consensus Estimate by 24.7%. You can see the complete list of today’s Zacks #1 Rank stocks here.
OPK has an estimated earnings growth rate of 23.3% for 2026. The company’s earnings beat estimates in each of the trailing four quarters, the average surprise being 95.1%.
Globus Medical, currently carrying a Zacks Rank #2 (Buy), reported a second-quarter 2026 adjusted earnings per share (EPS) of $1.34, which surpassed the Zacks Consensus Estimate by 19.6%. Revenues of $789.6 million beat the Zacks Consensus Estimate by 0.4%.
GMED has an estimated long-term earnings growth rate of 12.4%. The company’s earnings beat estimates in each of the trailing four quarters, the average surprise being 27.9%.
Merit Medical Systems, carrying a Zacks Rank #2 at present, reported second-quarter 2026 adjusted EPS of $1.19, which beat the Zacks Consensus Estimate by 23.9%. Revenues of $418.8 million surpassed the Zacks Consensus Estimate by 3.5%.
MMSI has an estimated long-term earnings growth rate of 10.4%. Merit Medical Systems’ earnings surpassed estimates in the trailing four quarters, with the average surprise being 14.1%.